by targeting the neovasculature. We previously reported that F8-IL-4, in combination with dexamethasone (DXM), provides a durable therapy in mice with collagen-induced arthritis (CIA). Therefore, the objective of this study was to identify the mechanism by which IL-4 and DXM combination therapy provides long-lasting disease remission. F8-IL-4 alone attenuated inflammation in CIA and this was associated with increased T H 2 and decreased T H 17 cell numbers in the joints. Similarly, DXM alone had an antiinflammatory effect associated with lower T H 17 cell numbers. In both cases, these therapeutic benefits were reversed once treatment was stopped. On the other hand, combination therapy with F8-IL-4 plus DXM led to a synergistic increase in the percentage of regulatory T (Treg) cells and antiinflammatory macrophages in the arthritic joint and spleen as well as IL-10 levels in serum and spleen. The net result of this was a more pronounced attenuation of inflammation and, more importantly, protection from arthritis relapse post therapy retraction. In conclusion, F8-IL-4 plus DXM is a durable treatment for arthritis that acts by promoting Treg cells in a synergistic manner, and by producing a sustained increase in antiinflammatory macrophages.
Introduction
Rheumatoid arthritis (RA) is a chronic autoimmune disease affecting joints, in which the delicate balance between pro-and antiinflammatory cells and their cytokines is perturbed. This is illustrated by the fact that targeting proinflammatory cytokines (TNF-α, IL-1β, and IL-6) in RA patients and in mouse models of RA, as well as boosting levels of antiinflammatory cytokines (IL-10 and IL-4) leads to a reduction in disease severity [1] [2] [3] . IL-4 is an antiinflammatory cytokine, which has been under investigation for the treatment of autoimmune arthritis since the late 1990s. IL-4 downregulates the production of proinflammatory cytokines such as IL-1, TNF-α, and IL-6, which have been implicated in the pathogenesis of RA [4, 5] . The ex vivo delivery of IL-4 has been shown to be effective in attenuating inflammation in mouse models of arthritis [2, 6, 7] . Furthermore, IL-4 has been identified in mice with arthritis during disease remission [8] , which suggests that this cytokine also plays a role in the resolution of disease.
IL-4 has an effect on a wide range of immune cells as its receptor is present on both T and B cells, mast cells, macrophages, monocytes, and fibroblasts [9] . IL-4 inhibits T H 17 cells [10, 11] , which are associated with joint inflammation and cartilage damage [12] . IL-4 plays an integral part in the induction of CD4 T helper 2 (T H 2) cells, by activating STAT6 and the transcription factor GATA3. IL-4 is also the signature cytokine secreted by T H 2 cells, which are known for their role in antibody-mediated immunity, responses against extracellular parasites, and in the development of allergic reactions such as asthma. It is well established that IL-4 in conjunction with IL-13 induces a state of alternate activation in macrophages, which are generally considered to be immunosuppressive [9, [13] [14] [15] [16] . IL-4 has been directly linked to the upregulation of genes associated with alternatively activated macrophages such as arginase, mannose receptor (CD206), FIZZ1, and Ym1/2 [9] . These findings suggest that the exogenous delivery of IL-4 is a viable therapeutic option in RA as well as in other inflammatory diseases. However, although recombinant IL-4 therapy has shown efficacy in psoriasis [17] , there are no documented successful trials in RA patients, possibly due to the fact that continuous delivery using miniosmotic pumps [2] or by repeated daily injections [17] is needed to reach a therapeutic concentration level at the site of inflammation. More importantly, nearly 50% of patients with psoriasis reported side-effects, such as headaches, with high doses of recombinant IL-4 [17] . The use of immunocytokines bypasses this problem as it enables the delivery and accumulation of cytokines at the site of disease [18] [19] [20] . F8-IL-4 is an immunocytokine (antibody + cytokine), which delivers recombinant IL-4 specifically to sites of inflammation by targeting the neovasculature. The F8 antibody recognizes the alternatively spliced extra domain A of fibronectin, which is expressed at sites of inflammation while being undetectable in healthy organs with the exception of sites of physiological angiogenesis [21] .
Sustained treatment-free remission in patients with autoimmune diseases has long been the unattainable holy grail of autoimmune disease treatment. Tolerizing strategies with dexamethasone (DXM) and immunogenic peptides have shown great promise in mouse models of diabetes [22] . We showed previously that F8-IL-4 attenuates collagen-induced arthritis (CIA) in DBA/1 mice, a preclinical model for RA [23] . More importantly, F8-IL-4 in combination with DXM, led to prolonged disease remission; however, the mechanism behind this phenomenon is not known. The preparation for phase I clinical trials in RA patients with F8-IL-4 are presently underway. The aim of the present study was to understand the mechanisms underlying the sustained therapeutic effect of F8-IL-4 and DXM by comparing the effect of monotherapy versus combination therapy on cells of the immune system, including myeloid and lymphoid cells. Our findings confirm those of others showing a significant therapeutic benefit with IL-4 alone [2, 7, 23] . In addition, we are the first to demonstrate that combination therapy leads to prolonged disease remission by the expansion of Treg cells and macrophages of an antiinflammatory and toleragenic phenotype.
Results

IL-4 delivery to arthritic joints attenuates inflammation in a mouse model of RA
First, we confirmed the ability of F8-IL-4 to attenuate joint inflammation in a well-established preclinical mouse model of RA. During the treatment regime, no adverse effects of F8-IL-4 or DXM were recorded. After 10 days of treatment, mice with CIA were culled and the influence of F8-IL-4 on cytokine levels in serum as well as on cells at the site of disease was determined (Fig. 1A) . As reported previously [23] , F8-IL-4 treatment reduced the arthritic scores in mice with arthritis. The therapeutic effect of F8-IL-4 was significant from day 4 of treatment onward. During the 10 day treatment period, there was no significant difference in the arthritic scores of mice receiving DXM monotherapy and F8-IL-4 + DXM combination therapy. Both DXM monotherapy and combination (F8-IL-4 + DXM)-treated mice showed a significant attenuation of disease in comparison to control (CTRL) animals from day 2 of treatment onward (Fig. 1B) .
As expected, increased levels of IL-4 were detected in the joints and serum of F8-IL-4 treated animals but not in the CTRL (PBStreated) or DXM monotherapy group. Of note was an induction of the antiinflammatory cytokine IL-10 in combination-treated mice. The levels of serum IL-10 in these mice correlated with IL-4 levels, suggesting that mice that respond to IL-4 treatment with the induction of IL-4 also induce IL-10 ( Fig. 1C) . Supernatants from arthritic joint cultures of F8-IL-4 + DXM-treated mice had a significant decrease in the production of proinflammatory cytokines: IL-1β, IL-6, GM-CSF, and IL-12 (Fig. 1D ). In addition, serum levels of IL-6, TNF-α, and IL-12 were also significantly lowered by F8-IL-4 + DXM treatment (Supporting Information Fig. 1A ). Surprisingly, the levels of TNF-α were higher in the paw cultures from mice that received F8-IL-4 monotherapy (Fig. 1D ). These findings suggest that although F8-IL-4 monotherapy can attenuate inflammation by inducing the expression of antiinflammatory cytokines such as IL-4 and IL-10, possibly some of its therapeutic effects are hindered by the induction of TNF-α in the inflamed joint.
F8-IL-4 synergizes with DXM to decrease T H 17/Treg cell ratios in arthritic joints
As F8-IL-4 had a significant influence on cytokines secreted by cells of the myeloid as well as lymphoid lineages, in our next set of experiments we examined the phenotype of cells found at the site of inflammation in more detail. The gating strategy used to identify lymphocyte populations using flow cytometry is shown in Supporting Information Fig. 2 . We found that the total number of cells isolated from joints on day 10 was comparable between treatment groups (Supporting Information Fig. 3A) . As predicted, F8-IL-4 treated mice had a significant increase both in the total number and the percentage of IL-4 secreting T H 2 cells in Values of p were calculated via one-way ANOVA with Dunnet's post-hoc test. *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001; ns: not significant.
the joint confirming the biological effect of therapy ( Fig. 2A and Supporting Information Fig. 3B ). F8-IL-4 treatment had no effect on IFN-γ levels in serum, in paw culture supernatants or on T H 1 cell numbers in the paw (Supporting Information Fig. 3C and data not shown). Conversely, the numbers of CD4 + and TCRγδ T cells secreting the proinflammatory cytokine, IL-17A, as well as the level of IL-17A detected in the paws was decreased by treatment with F8-IL-4 alone, DXM alone, or F8-IL-4 + DXM ( Fig. 2B-D) . It has been reported that IL-4 has a negative effect on the percentage of Treg cells among CD4 + T cells [24, 25] . We found that there was no significant effect of IL-4 on the Treg population ( Fig. 2E ). Although the total number of T H 17 was significantly reduced by F8-IL-4 alone, the ratio between proinflammatory T H 17 and suppressor Treg cells was not significantly changed ( Fig. 2F ). DXM is a well-known immunosuppressant that induces Treg cells [26] . Therefore, we hypothesized that DXM would support Treg numbers in F8-IL-4 treated mice and thereby improve clinical outcomes. DXM monotherapy led to a trend toward an increased proportion of Treg cells among CD4 + T cells in the paws of CIA mice, but the increase was not significant. However, F8-IL-4 + DXM induced a significantly higher percentage of Treg cells in comparison to DXM monotherapy. This contributed to a significant decrease in the T H 17/Treg cell ratio in the joints of arthritic mice.
F8-IL-4 plus DXM induces an antiinflammatory phenotype in macrophages in arthritic mice
As our previous results suggested that F8-IL-4 in combination with DXM has an effect on cytokines secreted by cells of the myeloid lineage, such as IL-1β, IL-6, and IL-12 we investigated the effects on myeloid cell number, phenotype, and activation. First, we examined the effect of F8-IL-4 treatment on macrophage, neutrophil, and dendritic cell numbers in mice with CIA. The gating strategy used to identify myeloid populations using flow cytometry was described in [27] and is shown in Supporting Information Fig. 4 . All treatment groups had an increase in the percentage of F4/80 expressing myeloid cells (data not shown). A reduction in the total number of paw macrophages was observed in DXM-treated animals (Fig. 3A) . F8-IL-4 + DXM as well as DXM monotherapy did not affect the total numbers of neutrophils or DCs in the paw (Supporting Information Fig. 5A and B). In our next set of experiments we addressed the hypothesis that the combination of F8-IL-4 plus DXM supports macrophages of a tolerogenic phenotype while inhibiting proinflammatory phenotypes. Indeed, combination-treated mice showed a significant increase in the M2-associated marker, CD206 (Fig. 3B ). There was a significant decline in the percentage of macrophages expressing MHC class II in combination-treated mice, suggesting a lower level of cell recruitment from other myeloid cell compartments such as the bone marrow. Combination-treated mice also showed a significant decrease in the percentage of MHC class II high macrophages, which suggests that combination therapy leads to a reduction in macrophage activation (Fig. 3C ). In addition, F8-IL-4 + DXM mice showed a higher expression of other M2-associated markers such as Arg1, Il10, and Ym1 as well as a lower expression of M1-associated markers (Il12b). On the other hand, DXM induced the expression of Nos2 (Fig. 3D ). Arginase mRNA (Arg1) expression levels in combination-treated mice correlated with their arthritic score (Fig. 3E ), but not their serum IL-4 levels (Supporting Information Fig. 5C ). This suggests that even though animals with high levels of IL-4 have also a higher expression of IL-10, Arg1 is best correlated with disease status of the animal.
F8-IL-4 plus DXM provides protection from arthritis relapse and inhibits IL-17A expression in joints
As combination therapy led to an increase in the proportion of antiinflammatory cell types, we examined whether these effects translated into clinical benefit and whether they were sustained in the long term. As in our previous experiments, arthritis was induced in DBA/1 mice. Once the mice showed signs of arthritis they were recruited to one of the two treatment groups (F8-IL-4 + DXM or DXM alone) and treated for a limited period of 10 days (Fig. 4A) . Once treatment was stopped there was a dramatic increase in the arthritic scores of mice receiving DXM alone (Fig. 4B) . However, mice receiving combination therapy maintained a significantly lower mean arthritic score in comparison to DXM monotherapy mice. Furthermore, withdrawal of DXM monotherapy led to a spread of disease to previously unaffected paws, which was not observed in the F8-IL-4 + DXM combination-treated mice. The mice were monitored daily until day 21 at which time point the mice were culled. Consistent with the clinical findings, combination-treated mice had lower numbers of cells in their paws at day 21 ( Fig. 4C ). Combination-treated mice also continued to have a low number of proinflammatory T H 17 and IL-17A + TCRγδ T cells, but interestingly these mice no longer showed a significant increase in the proportion of T H 2 cells ( Fig. 4D and E) . Serum and paw culture supernatant levels of IL-4 were below detection in combination-treated mice (data not shown). The number of T H 1 and Treg cells in the joints of combination-treated mice was identical to those of DXM mice; however combination mice had a significant decrease in the ratio between T H 17 and Treg cells ( Fig. 4F and Supporting Information Fig. 6A and B) . As on day 10 with the exception of TNF-α, supernatants from paw cultures of combination-treated mice showed a lower level of proinflammatory cytokines (Fig. 4G) . The antiinflammatory cytokine, IL-10 was still significantly higher in the serum (Fig. 4H ).
F8-IL-4 plus DXM-induced antiinflammatory macrophages persist after therapy retraction
In contrast to DXM monotherapy mice, F8-IL-4 + DXM-treated mice continued to have a smaller population of neutrophils in their paws. Post therapy retraction, there was no difference between the numbers of macrophages and DCs in the paws between treatment groups (Fig. 5A-C) . However, F8-IL-4 + DXMtreated mice continued to have a higher proportion of CD206-expressing macrophages, which suggests a long-term effect of F8-IL-4 + DXM on macrophage phenotype (Fig. 5D ). Combinationtreated mice continued to have a lower proportion of MHC class II positive macrophages (Fig. 5E ). Similarly as on day 10, on day 21 there was no significant difference in the expression of Nos2 between treatment groups. DXM-treated mice had a higher expression of IL-12b, which encodes the p40 subunit of IL-12 and IL-23 and is associated with M1 macrophages. In contrast, genes associated with tolerogenic M2 macrophages (Arg1, Il10) were expressed at higher levels in the spleens of combination-treated mice in comparison to DXM monotherapytreated mice (Fig. 5F ). Arginase mRNA (Arg) expression levels correlated with the arthritic scores of combination-treated mice on day 21 (Fig. 5G ).
Discussion
In this study, we sought to elucidate the mechanism of action of IL-4 and DXM combination therapy in arthritis. Recombinant IL-4, as well as F8-IL-4, have shown efficacy in mouse models of RA [2, 23, 28] . We confirmed and extended these findings by demonstrating decreased T H 17 and increased T H 2-type responses at the site of disease activity following treatment with F8-IL-4. The antiinflammatory properties of IL-4 were first described in the early 1990s in which it was linked to the downregulation of TNF-α, IL-1, and IL-6 [4, 5, 29] . Indeed in our hands, F8-IL-4 treatment alone significantly reduced the levels of IL-1β and IL-6 in arthritic joints. We were intrigued to find that F8-IL-4 increases local TNF-α level in paws, but not in the serum of arthritic mice. There are data suggesting that IL-4 can increase TNF-α production by murine peritoneal macrophages in some circumstances [30] , a phenomenon that it not true for LPS-stimulated TNF-α production by these cells [31] . Therefore, it is possible that IL-4 may have contrasting effects on macrophages based on their localization or state of activation and possibly even phenotype. Even species differences have been noted, as human macrophages do not behave in this way as the presence of IL-4 is known to inhibit TNF production [4] . The mechanism behind the increase in TNF-α is unknown, but it could possibly explain the relatively low level of efficacy of F8-IL-4 monotherapy and suggests that F8-IL-4 would act synergistically with TNF-α inhibitors.
Studies have shown that IL-4 can influence T H 17 cells indirectly by the downregulation of IL-23, which is needed for the stability of T H 17 cells [32] or directly by opposing IL-17A expression [10, 11] . All three treatment regimens used in this study decreased T H 17 numbers in inflamed joints. Consistent with this were lower levels of IL-17A detected in paw culture supernatants. Various studies point toward the importance of IL-17A in the pathogenesis of RA (reviewed in [33, 34] ). Blocking IL-17A in animal models of arthritis protects from joint and cartilage damage and leads to significant clinical improvements [35] . Surprisingly in contrast to what has been observed in animals models, in clinical trials with RA patients targeting IL-17A alone has been relatively disappointing [36] , suggesting that other cytokines produced by T H 17 cells (GM-CSF, TNF-α) also may play a role in RA.
IL-4 therapy may have some negative effects on immunosuppressive cells as it has been reported to indirectly influence tolerance-inducing regulatory T (Treg cells) cell numbers [24, 25] . In this study, although F8-IL-4 did not significantly reduce Treg total numbers in arthritic paws, we observed a tendency for IL-4 to reduce the percentage of FoxP3 + Treg cells among the CD4 + T-cell population. This result suggests that although IL-4 induces a significant decline in T H 17 cells, the T H 17/Treg ratio is not significantly changed. We hypothesized that boosting Treg numbers in F8-IL-4 treated mice would further enhance the previously described therapeutic effects of IL-4. DXM is a synthetic glucocorticosteroid that is well known for its immunosuppressive effects. We chose to use DXM in this study as it is already used in RA patients [37] and it targets T H 17 cells [38] and supports Treg cells [26, 39] as well as toleragenic macrophages [22, 26, 40] . DXM is often used in RA patients either alone or more often in combination with so-called disease-modifying antirheumatic drugs or biologics such as anti-TNF. However, severe adverse effects, such as osteoporosis, mood changes including depression and anxiety as well as aggravation of diabetes limit DXM use in patients. More importantly, the risk of these side-effects increases with higher doses (>10 mg/day) and the duration of therapy. Therefore, the European League against Rheumatism recommends to only use low-dose glucocorticosteroids for up to 6 months and to only consider this treatment as part of an initial treatment strategy in combination with one or more disease-modifying antirheumatic drugs [41] . Although it is difficult to compare treatment regimens between humans and mice due to interspecies physiological differences, in our study to limit the toxic effect of DXM, we used a relatively low dose of DXM and a treatment period of only 10 days. We found that combination therapy (F8-IL-4 + DXM) led to a more pronounced attenuation of inflammation than F8-IL-4 monotherapy. Significantly, in comparison to DXM monotherapy, a further expansion in the proportion of Treg cells as well as an increase in the proportion of antiinflammatory macrophages in the arthritic joint and spleen were observed in combination-treated mice. An important question that arises from this study is whether the antiinflammatory macrophages that are induced in combination-treated mice dependent on Treg cells. Indeed, studies have shown that Treg cells can induce M2 macrophages [42] in mice and alternatively activated macrophages in humans [43] . At least, in mice, Treg induction by M2 macrophages seems to be dependent on multiple factors including arginase, IL-10, and TGF-β [42] . Conversely, the opposite is also true, as antiinflammatory macrophages can induce Treg cells in mice and in man in processes dependent on IL-10, TGF-β, and retinoic acid [44, 45] . Alternatively, a third possibility could be envisioned in our study in which both subsets have developed independently of each other as DXM has been shown to induce both subsets [26, 40] .
IL-10 is a potent antiinflammatory cytokine that protects the host from immune-mediated damage. The exogenous delivery of IL-10 has been shown to attenuate CIA [18, 19, 46, 47] possibly by targeting proinflammatory T H 17 cells [48, 49] . Although we do not know which cell type(s) in our study produced the IL-10, it has been shown to be expressed by tolerogenic subpopulations of macrophages as well by T H 2 and Treg cells, but under certain circumstances is also produced by T H 1 and T H 17 cells making them less pathologic [50] . It has recently been reported that IL-4 induces IL-12, which in turn is needed for the induction of T H 1 responses [51] . In our study, although F8-IL-4 monotherapy did increase circulating IL-12 levels in the serum, combination therapy drastically decreased these levels. Furthermore, neither F8-IL-4 nor F8-IL-4 + DXM-treated mice showed an increase in IFN-γ or T H 1 responses. One possible explanation for these contradictory findings may be that targeting of IL-4 to sites of inflammation, in contrast to systemic administration, leads to IL-10 induction and thereby counteracts the effects of IL-12 on T H 1 cells.
Inflammatory macrophages have been described in the synovium of RA patients where they secrete proinflammatory cytokines such as TNF-α and IL-1β, which further support the inflammatory process [52] , thus making them valid targets in RA. Macrophage polarization is orchestrated by the cytokine milieu. Inflammatory macrophages are induced by LPS or bacteria, and/or IFN-γ, or GM-CSF. In contrast, macrophages can acquire an alternative state of activation in the presence of IL-4 and/or IL-13, IL-10 and/or M-CSF. Noteworthy is the fact that in our study F8-IL-4 + DXM combination treatment leads to the induction of a gene signature characteristic of alternatively activated macrophages. Alternatively activated macrophage markers such as arginase, mannose receptor (CD206), FIZZ1, and Ym1/2 are known to be induced by IL-4 [9] . This would suggest that IL-4 and DXM combination treatment, along with the induction of IL-10, leads to the upregulation of markers associated with alternatively activated macrophages, which support tissue healing. In accordance with this observation, mice that had high levels of IL-4 in their serum on day 10 had a high level of IL-10 in their serum.
Unexpectedly, IL-4 levels in serum did not correlate with the total arthritic scores of mice, but to levels of IL-10. On the other hand, arginase did correlate with the total arthritic score of F8-IL-4 + DXM-treated mice. This would suggest that IL-4 has an indirect effect on disease severity, possibly by inducing other antiinflammatory factors such as arginase in macrophages. This is further supported by the observation that animals with a higher level of arginase expression on day 21 also had a lower arthritic score. In addition, the level of IL-4, in contrary to arginase, decreased once treatment was stopped and it was no longer detected in combination-treated mice on day 21.
As combination therapy in comparison to DXM monotherapy led to an increase in the proportion of antiinflammatory cell types, we hypothesized that these effects could be sustained in the long term after therapy retraction. As shown previously [23] , F8-IL-4 + DXM, but not DXM-treated mice, were protected from arthritis relapse post therapy retraction [23] . The experiment was terminated at day 21 post disease onset due to the high arthritic scores of DXM monotherapy mice. An examination of the phenotype of cells infiltrating the arthritic joints revealed that combinationtreated mice still had a significant decrease in the number of T H 17 cells and neutrophils. In addition on day 21, combination-treated mice had a higher level of IL-10 and also an antiinflammatory macrophage gene signature. Although both groups had a similar number of Treg cells at the site of disease, only combination mice were able to maintain a significantly lower ratio between T H 17 and Treg cells. In conclusion, F8-IL-4 and DXM combination therapy is a durable treatment for arthritis that acts by supporting the generation of Treg cells, and by providing an environment for antiinflammatory macrophages.
Materials and methods
Induction and assessment of arthritis
Arthritis was induced in DBA/1 mice as described previously [53] . Briefly, bovine type II collagen was purified from articular cartilage and dissolved in 0.1 M acetic acid. Ten-to 12-week-old male DBA/1 mice (Harlan UK) received one subcutaneous 100 μL injection of 200 μg bovine type II collagen in complete Freund's adjuvant (BD Biosciences), at the base of the tail and on the flank.
Post immunization, the mice were monitored daily for signs of arthritis. Once an animal showed signs of arthritis (redness and/or swelling of front or hind paw joints) it was randomly assigned to a treatment group and monitored daily. Arthritis severity was scored as follows: 0 = normal paw, 1 = slight swelling and/or erythema, 2 = pronounced swelling, 3 = ankylosis. All four limbs were scored blindly, giving a maximum possible score of 12 per animal. Hind paw swelling was measured daily with calipers (Kroeplin).
Mice were maintained under specific pathogen-free conditions with food and water available ad libitum. All procedures were approved by the Clinical Medicine Animal Welfare Ethical Review Board and the UK Home Office in accordance with the Animals (Scientific procedures) Act 1986.
Drugs
The immunocytokine, F8-IL-4 (owned by Philogen Spa) is a fusion protein between murine IL-4 and the single variable chain of the F8 monoclonal antibody, and has been described in more detail elsewhere [23] . DXM (Sigma-Aldrich) was dissolved in PBS to a concentration of 1 mg/mL and stored at 4°C. Where specified, animals received daily intraperitoneally 100 μL of DXM (100 μg per mouse) or PBS (CTRL). F8-IL-4 treated animals received three doses of 100 μL (100 μg per mouse) of F8-IL-4 on day 1, 4, and 7 post disease onset. Analgesia was provided in the form of Novalgin (Analgin; Sanofi-Aventis) added to the drinking water (1.3 g/L). The water bottles were changed twice per week. Mice with long-standing arthritis (longer than 10 days), received additional daily subcutaneous injections of Novalgin (200 μg/kg).
Analysis of immune responses in arthritic mice
The experimental design is depicted in Figures 1A and 4A . All mice with clinical arthritis were treated from day 1 to 10 of arthritis. On day 10 some animals were culled whereas others were kept until day 21 before being culled. In both cases peripheral blood, spleen, and paws were taken. A single-cell suspension of joint cells was prepared from paws as follows. After skin removal, each arthritic paw was digested in 1 mL of 0.1 mg/mL DNase I and 0.313 mg/mL Liberase (both from Roche Diagnostics) for 90 min. Cells were cultured in RPMI-1640 with L-glutamine, 10% fetal calf serum, and penicillin/streptomycin (all from Life Technologies). To detect cytokine secretion, joint cells were stimulated with an anti-CD3ε antibody (clone 145-2C11, eBioscience). After 48 h culture supernatants were taken for cytokine quantification.
Flow cytometric analysis
Joint cells were stimulated with 0.02 μg/mL PMA, 0.4 μM ionomycin, and 1.25 μg/mL brefeldin A (all from Sigma-Aldrich) for 4 h. The antibodies used for surface and intracellular stainings of mouse cells are listed in Supporting Information Table 1 . The cells were fixed and permeabilized with the buffers provided with the FoxP3 Staining Buffer Set (eBioscience). Live cells were identified using the Zombie Fixable Viability Kit (BioLegend). Data were acquired on a CANTO II flow cytometer using FACSDIVA software (all BD Biosciences) and analyzed using FlowJo software (Tree Star, Inc.).
Cytokine detection
Cytokines were detected in serum and 48-h anti-CD3ε stimulated joint cell culture supernatants using the Meso Scale Discovery platform according to manufacturer's specifications.
RNA isolation and quantitative real-time PCR
Total RNA was isolated using the RNeasy Mini kit (Qiagen). cDNA was transcribed using the Reverse Transcription System (Promega). For quantitative PCR, reactions were performed using TaqMan primers and probes (Applied Biosystems). Probes used are listed in Supporting Information Table 2 . All procedures were done according to the manufacturer's instructions. The comparative threshold cycle (C T ) method ( C T ) was used for relative quantification of gene expression.
Statistical analysis
Data are presented as the arithmetic mean ± SEM. Comparisons between two groups were carried out using an unpaired Student's t-test (two-way). For more than two groups, ANOVA was used followed by Tukey's (two-way) or Dunnett's (one-way) post-hoc test. Correlations were tested using the Spearman's correlation coefficient for nonparametric data and the Pearson's correlation coefficient for parametric data. Probability values (p) of less than 0.05 were considered significant. Statistical analysis was performed using GraphPad PRISM (GraphPad Software Inc.).
